by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : March 2005
A HEXAL ADVERTORIAL Hexal signs licensing agreement with GSKA A new, less expensive range of lamotrigine tablets will be marketed under the name Lamitrin® following a licensing agreement between GlaxoSmithKline Australia (GSKA) and Hexal. Hexal is one of Australia’s fastest growing generic pharmaceutical companies.The dispersible and chewable Lamitrin is PBS listed as an Authority Item for the second line treatment for epileptic seizures not satisfactorily controlled by other anti-epileptic drugs. Hexal Marketing Director Mike Hobbs said the German-based pharmaceutical company Hexal AG* is the world’s fourth largest generic pharmaceutical manufacturer. ‘Hexal Australia is now in another major growth phase with plans to release a variety of blockbuster medications as Hexal brands,’ Mr Hobbs said.‘Our expansion is timely because of changing market demographics and an increased proportion of Australia’s population requiring medication at a more affordable price, particularly since patient co- payments increased in January 2005 by more than 20%.’ Hexal will offer Lamitrin as a benchmark-priced range of lamotrigine with resultant savings to sufferers of epileptic seizures.‘The chewable and dispersible Lamitrin tablets assist patients with epilepsy to take an important medication at the correct time,’ said Mr Hobbs. Lamitrin tablets are also identical in appearance to Lamictal® .This will reassure both patients and pharmacists as anticonvulsant medications tend to be treated with even more sensitivity than most other medications. The Lamitrin range will feature the distinctive, pharmacy and patient-friendly Hexal packaging.The Hexal packaging is designed for easy recognition of dosage strength by using distinctive combinations of colours. And as with other Hexal packaging, the Lamitrin packs will carry the active ingredient (lamotrigine) in large lettering on the back labeling panel of blister cartons to assist patients avoid double dosing if, or when, they change their brand of lamotrigine. PBS Information: Authority required. Please refer to Schedule of Pharmaceutical Benefits for full authority prescribing information. *Hexal is based in Germany and Hexal AG is the fourth largest generic pharmaceutical company in the world. Hexal Australia is the Australian subsidiary and currently distributes more than 130 lines with plans to expand its significant range of prescription medications including the rollout of more than 50 more actives and more than 200 lines. Lamictal and Lamitrin are registered trade marks of the GlaxoSmithKline Group of companies. THE AUSTRALIAN JOURNAL OF PHARMACY VOL.86 MARCH 2005 ? 181